15ICML 280--P • • • • • • Cohort 1: FL; cohortcohortFL; Cohort 1: 2: DLBCL;3: patientsin thesafetyincluded We present here safetyearly response and data the of in R/RNHLs. combinationof evaluatingthe efficacy safetyand ofthe chemotherapy The LYSA conductsmulticenter a trialphase II (NCT03276468) treatment paradigm. enhance anti tumor Combining BCL smallmolecule inhibiting cells cytotoxicity,lymphoma inducing whereas respectivelyacting toT inhibit (R/R NHLs)treatment remains challenging. immunochemotherapy,relapse refractoryand B Despitemajor advances introducedby Atezolizumab • • Efficacy • • • • • • Safety • • • • The OverallMetabolic Response Rate (OMRR)was At(after intermediateanalysis C themto due progression. ( Four patients No tumorsyndrome lysis observed. was All thesenon ( The mostcommonnon experienced No patient febrile neutropenia. G with D Median time ofexposure: Median up:follow age was Median A total of 3 uring the uring • • → [ 23 5 3 9 %] pts),%] diarrhea ( Charles HERBAUX ≥ ( ( and DLBCL 42 25 3 Introduction Charles Herbaux NOVEL TREATMENTS - neutropenia ( 13 %, %, tumor immunity representsimmunitytumor an attractive and 4 atezolizumab patients were patients enrolled inthesafety firstcycles of treatment,hematologic toxicitythecommonAE, was most 3 3 - hematologic AEwere G - 3 FL and FL achieved complete metabolicDLBCL) response(CMR) targeted therapies withagents that obinutuzumab B 1 C refractory Safety and efficacy of DLBCL and DLBCL 61.7 é Background H 4 . Herbaux nite é 4.4 FL matologie years [ , 2 France; months [ - 7 2 DLBCL) achieved partialmetabolicresponse DLBCL) (PMR) hematologic all [ , obinutuzumab and venetoclaxand obinutuzumab, [ - 54 15 - 2. - 18 lymphocyteexhaustion or by run. 1 %] pts) and G %] pts) and 39 %] pts)IRR ( %] and , CHRU de Lille,Lille,de CHRU , FL) have permanently discontinued study treatment,studyof all permanentlydiscontinued have FL) 5 weeks [ are monoclonal antibodies - 1 Hematology,de Grenoble, CHU 77 3.5 4 , P. Feugier ), ] non - 12 Results 5.1 iNHL 1 6 patients were patients evaluableforresponse: or - ] - 21 grade AEwere infections( - ≥ 2 ] Hodgkin lymphomas: Results from the 3 , exceptoneG venetoclax - thrombocytopenia( 2 lymphomas France; [ 2 15 , H.Tilly - run between Feb and Aprrun between Feb and %] pts).%] 67 - free % ( 2 is a atezolizumab Hematology 8 3 out of out Grenoble,France; lung infection.lung 3 , G. Salles 4 12 , 15 6 [ CHU Nancy CHU 31 ). [ - 46 ICML, Lugano,ICML, Switzerland, 2019 %] pts). %] pts), back pain %] pts), 4 6 , GressinR. 2018 Hematology,Nantes,de CHU Nantes , VANDOEUVRE A AT G , obinutuzumab and venetoclax combination for BT A DOI: 10.3252/pso.eu.15ICML.2019 : EZOLIZUMAB - 101 - 199 :venetoclax - 5 L È , S. LeGouill S • • • • - • • • • NANCY, NANCY, Treatment The neutropenia The tolerated The No cohortThe DLBCL reached numberplaned its On thesedata, theDataSafety and Monitoring tumoral A pseudo recruiting of patients.and FL prophylaxisa primary adding G with Board decidedto of inclusions in of inclusions OMRR unexpected toxicitybeen observed has todate atezolizumab Data France; metabolic progression athas showed C4,and aCMRat C8 - and and progression was observed retrospectively one FLpatient.in He was in of Cedex 3 6 67 , F. Morschhauser Hematology, CHU de, Rouen, CHU de, Hematology, Poster safety follow Safety % the main part ofthe the main , 1 allow allow the is presented , obinutuzumab iNHL France; encouraging - • • • • • • • up Monitoring includeat least 12patientstreated at least 6weeks (2C). Before enteringstudy, inthemain the safety the safetycombination. ofthis endpointThe primaryofthe safety startedfor D8C1 on 24 cycles. cycles. atthen administered D2ofC1, at D2ofeach cycle for 24 every 3 weeks. 15 ofcycle8 and (D) 1, from onD1 and (C) 1 to C2 C8 therapeutic combination. safetyAn initial anthracyclineand containingregimen) were eligible. who failedor FL) at least oneline therapy of (rituximab Patientsyears ≥18 biopsywith cohorts are still - at: Venetoclax Atezolizumab Obinutuzumab of run 7 these Hematology,Montpellier, CHU Montpellier Printing of for supported continuation patients Conclusion Discussion and Board - was givenat orallydose, full at 800mg/D a trial, aftertrial, CSF 1 GATA Discussion chemo , was given IV,1200g every 3 weeks, started France; venetoclax - by G was given IVat thedose 1000 of g onday run was performed toassess novel this : . Cartron are decided - 4 free currently Method , a Hematology, regimen combination LYSA study to BOOK - 7 confirmedR/R NHL (DLBCL add . ongoing H - in run was toevaluate Nr ô primary pital R/R . 280 appears Cedex Lyon Lyon . NHLs relapsed - run had torun had prophylaxis Sud 5 , France, , to Pierre be . - well of